Lung cancer trials in Japan

In Japan 135 Also abroad 2747

135 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Akashi-shi, Bunkyo-ku, Bunkyo Ku, Chuo Ku, Hirakata-shi, Kashiwa, Kurume-shi, Nagoya, Natori-shi, Niigata, Sapporo, Toyoake
Age
18 years and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Aichi, Nagoya, Aichi, Toyoake, Chiba, Kashiwa, Fukuoka, Fukuoka, Fukuoka, Kitakyushu, Hiroshima, Hiroshima, Hokkaido, Sapporo, Kanagawa, Sagamihara, Kanagawa, Yokohama, Miyagi, Sendai, Niigata, Niigata, Okayama, Okayama, Osaka, Hirakata, Osaka, Osaka, Osaka, Sakai, Saitama, Hidaka, Saitama, Kitaadachi-gun, Shizuoka, Sunto-gun, Tochigi, Shimotsuke, Tokyo, Bunkyo-ku, Tokyo, Chuo-ku, Tokyo, Koto-ku, Tokyo, Shinjuku-ku, Wakayama, Wakayama
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
Phase 3Taking people
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Where
Tokyo
Age
18 years and over
People
1,200 worldwide
Run by
Takeda
See details and how to joinNCT07217301 · EU 2026-525659-94-00
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Akashi, Fukushima, Hidaka-shi, Iwakuni, Kanazawa, Kashihara, Nagasaki, Nagoya, Nankoku-shi, Nishinomiya-Shi, Osaka, Sagamihara, Sakai-Shi, Sendai, Toon-shi, Toyama
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Bunkyo-ku, Chuo-ku, Fujieda-shi, Fukuoka, Fukushima, Fukuyama, Habikino-shi, Higashiibaraki-gun, Hirakata-shi, Hirosaki-shi, Hiroshima, Kasama-shi, Kashiwa-shi, Kitakyushu-shi, Kobe, Kumamoto, Kurashiki-shi, Kurume-shi, Meguro-ku, Miyazaki, Nagaoka-shi, Nagoya, Natori-shi, Osaka, Ota-shi, Sagamihara-shi, Sakai-shi, Sapporo, Sendai, Shinagawa-ku, Shinjuku-ku, Shiwa-gun, Takarazuka-shi, Toyama, Tsu, Ube-shi, Utsunomiya, Wakayama, Yamagata, Yokohama
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 3Taking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Chiba, Fukuoka, Hirakata, Hirosaki, Kanazawa, Kashiwa, Kawasaki, Kitaadachi-gun, Kobe, Koto, Matsusaka, Nagoya, Nankoku, Niigata, Osaka, Ōta, Ōta-ku, Sendai, Shimotsuga-gun, Shinjuku, Takarazuka, Tōon, Toyoake, Ube, Ureshino, Yokohama
Age
18 years and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Amagasaki-shi, Bunkyō City, Chūōku, Fukuoka, Hirakata-shi, Hiroshima, Kakogawa-shi, Kanazawa, Kawagoe-shi, Kawasaki-shi, Kitaadachi-gun, Kitakyushu-shi, Kiyose-shi, Kobe, Kōtoku, Kumamoto, Kyoto, Matsusaka-shi, Obihiro-shi, Osaka, Ota-shi, Saitama-shi, Sakai, Sapporo, Sendai, Shinjuku-ku, Takaoka-shi, Yokohama
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
Phase 1Taking people
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Where
Hirakata, Koto-Ku
Age
18 years and over
People
404 worldwide
Run by
Astellas Pharma Inc
See details and how to joinNCT07094204 · EU 2025-522082-29-00
Phase 3Taking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Bunkyō City, Fukuoka, Hakodate-shi, Hidaka-shi, Hirakata-shi, Hirosaki-shi, Hiroshima, Kanazawa, Kashiwa, Kawasaki-shi, Kumamoto, Matsusaka-shi, Matsuyama, Nagoya, Niigata, Okayama, Osaka, Osakasayama-shi, Sagamihara-shi, Sapporo, Takaoka-shi, Takatsuki-shi, Tokushima, Tokyo, Utsunomiya, Yokohama
Age
18 years and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Amagasaki-shi, Bunkyō City, Chūōku, Fukuoka, Hiroshima, Kawagoe-shi, Kawasaki-shi, Kitaadachi-gun, Kitakyushu-shi, Kiyose-shi, Kobe, Kōtoku, Kumamoto, Kyoto, Matsusaka-shi, Obihiro-shi, Osaka, Ota-shi, Saitama-shi, Shinjuku-ku, Sunto-gun, Takaoka-shi, Yokohama
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
Phase 1/2Taking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Bunkyō City, Kashiwa, Kurume-shi, Kyoto, Niigata, Shinjuku-ku, Toyoake-shi
Age
18 years and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
Phase 1/2Taking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Chuo-Ku, Hirosaki, Koto-ku, Kyoto, Nagasaki, Nagoya, Niigata, Takatsuki, Yokohama
Age
18 years and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Aomori, Bunkyo Ku, Fukuoka, Hamamatsu, Hidaka, Hirakata, Nagasaki, Nagoya, Osaka, Sagamihara, Sapporo, Sendai, Toyoma
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 2Taking people
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Where
Bunkyo Ku, Chuo-Ku, Kashiwa-shi, Sunto-gun, Wakayama
Age
18 years and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-chō, Nagoya, Osakasayama-Shi, Saitama, Tokyo, Yokohama
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Where
Chuo Ku, Koto-ku
Age
18 years and over
People
392 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07730021 · EU 2026-525938-31-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Hidaka-shi, Hirakata-shi, Hirosaki-shi, Kashiwa-shi, Kawasaki-shi, Kitakyushu-shi, Kumamoto, Kurume-shi, Matsusaka-shi, Okayama, Osaka, Ōta-ku, Sakaishi, Sapporo, Shinjuku-ku, Sunto-gun, Toon-shi, Toyoake-shi, Wakayama, Yokohama, Yonago-shi
Age
18 years and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
Phase 2/3Taking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Bunkyo-ku, Fukuoka, Hidaka, Himeji, Hirakata, Kashiwa, Kawasaki, Kobe, Matsusaka, Nagoya, Nankoku, Okayama, Osaka, Otashi, Sapporo, Sendai, Shimotsuga, Shiwa-gun Yahaba-cho, Ube, Yokohama
Age
18 years and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Aomori, Funabashi, Hamamatsu, Hidaka, Hirakata-shi, Hiroshima, Kamakura, Kanazawa, Koshigaya, Kumamoto, Nishinomiya, Sakai, Sapporo, Sendai, Tōon, Toyohashi, Yokohama
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 2Taking people
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Fujieda, Kashiwa-shi, Kobe, Kurashiki-shi, Miyazaki, Nagoya, Sagamihara-shi, Sapporo, Sendai, Wakayama
Age
18 years and over
People
150 worldwide
Run by
AbbVie
See details and how to joinNCT06568939
Phase 1/2Taking people
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Where
Chuo Ku, Hirakata-shi, Kashiwa-shi, Koto-ku
Age
18 years and over
People
428 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07287995
Phase 2Taking people
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Where
Chuo Ku, Kashiwa, Nagoya, Yokohama
Age
18 years and over
People
320 worldwide
Run by
Pfizer
See details and how to joinNCT04606446
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kobe, Miyagi, Nigata-shi, Okayama, Osaka, Saitama, Tokyo
Age
18 years and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
Phase 3Taking people
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Where
Asahikawa, Bunkyo-ku, Bunkyō-Ku, Fukuoka, Hirakata, Hiroshima, Izumi, Kashihara, Kashiwa, Koshigaya, Koto-ku, Kurume, Matsumoto, Ōmura, Osaka, Sakai, Sapporo, Sendai, Shimosuga, Shinjuku-Ku, Shizuoka, Yokohama
Age
18 years and over
People
480 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146
Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Kashiwa
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00